remed

About REMED

REMED grows with its customers.

REMED has been producing and supplying core components and medical devices related to electronic medication, focusing on "treatment of intractable brain diseases" and "non-invasive procedures," since its establishment 20 years ago. From the early stages of the development of major neural modulation technologies in Korea such as Transcranial Magnetic Stimulation (TMS), Neural Magnetic Stimulation (NMS), and Core Strength Magnetic Stimulation (CSMS), REMED has been growing with customers based on deep-rooted trust.

REMED strives to provide greater added value and satisfaction as a specialized company in the field of electronic medication. Based on the technology and experience accumulated so far, REMED aims to expand clinical indications, strengthen overseas businesses in the US, Europe, and China, and achieve sustainable growth.

Furthermore, by supplying more technologically differentiated products and solutions, REMED aims to become the undisputed global No.1 specialized company in electronic medication. REMED will be a company that fulfills robust social responsibilities and builds a sustainable corporate ecosystem.

  • Kosdaq
  • FDA
  • CE
  • 글로벌 강소기업
  • K-inno medtech

Mission & Vision

Creativity and Challenge
Encouraging the spirit of creativity and challenge, guarding against complacency, and constantly pursuing innovation.
Value of Core Technology
Considering technology as a core value and aspiring to be a First Mover leading the global market.
Value Sharing and Restoration
Pursuing the spirit of sharing and restoring value for society rather than staying solely focused on profit generation.
Support for Failure
Respecting a spirit free of fear and sparing no support for failure.

History

2024

  • Selected as an innovative medical device company

2023

  • Launch of "BrainStim"
  • Establishment of REMED Japan branch
  • 5-year supply contract for pain treatment equipment to China's S company

2021

  • FDA approval
  • Top exporter with $10 million in exports

2020

  • Selected as KOSDAQ Rising Star
  • Selected as a great place to work

2019

  • Listed on KOSDAQ
  • Achieved $5 million in exports
  • Attracted $500,000 investment from Germany's Z company
  • Launched and supplied CSMS products for aesthetic purposes to the US market in 2019

2018

  • Selected as K-brain power Excellent Enterprise
  • Achieved $3 million in exports

2017

  • Supply contract for Neural Magnetic Stimulation (NMS) with Germany's Zimmer
  • Government project approval
  • Support for the development of FSWT devices for the Chinese market: $1.5 million
  • OEM contract signed with major European companies

2016

  • Obtained Japan Medical Devices Act (JFDA) approval
  • Selection for the Ministry of Industry's government project "Development of Dementia Treatment Devices"
  • Government project approval for "Dementia Treatment Device"

2015

  • Selection as a next-generation world-class product for depression treatment devices
  • FDA approval in Japan

2014

  • Depression treatment device certified as Korean New Excellent Technology (NET)
  • MOH New Technology Certification
  • Attracted investment from major events

2013

  • Completion of China FDA approval
  • Completion of Russia FDA approval
  • TMS KFDA approval
  • Confirmation of international certifications in China and Russia

2010

  • Selected as a leading company in the government project of the Ministry of Health and Welfare
  • Development of "Brain Navigation-embedded Brain Stimulation Therapy Device"

2009

  • Commencement of exports to European countries

2008

  • ISO 13485 approval
  • Investment from the Korea Development Bank

2007

  • Initiation of clinical trials for depression treatment using TMS, a first in Korea
  • Received Excellent Award at the Korea Health Industry Technology Fair
  • Clinical trials conducted at university medical centers

2004

  • Establishment of Corporate R&D Center
  • Selected as a leading company in the government project "Electromagnetic Field"

2003

  • Company Establishment
  • Launch of the world's first Neural Magnetic Stimulation Therapy Device (NMS)